Macina Denis, Evans Keith E
Global Medical, Sanofi Pasteur, 14 Espace Henry Vallée, 69007, Lyon, France.
inScience Communications, Chowley Oak Business Park, Chowley Oak Lane, Tattenhall, Cheshire, UK.
Infect Dis Ther. 2021 Jun;10(2):719-738. doi: 10.1007/s40121-021-00440-8. Epub 2021 Apr 27.
Despite modern diphtheria-tetanus-pertussis (DTP) vaccines and high vaccine coverage, a resurgence of pertussis (whooping cough) has been observed globally. In North America and Europe, high vaccine coverage in children has led to a shift in the age-specific peak incidence of infection away from infants and towards older children and adolescents. However, much less is known about the prevalence of pertussis in older children and adults in the Middle East. A systematic search of MEDLINE, EMBASE, and BIOSIS was undertaken to identify studies published between 1 January 1990 and 17 June 2019, with information on pertussis epidemiology, burden of illness, and mortality in school-aged children, adolescents, and adults in the Middle East. Studies identified for inclusion were reviewed narratively because a statistical comparison was not possible because of the mix of methodologies used. The results showed that surveillance data are weak or missing in most Middle Eastern countries, and among 24 epidemiological studies identified, most were from Iran (14), Israel (4), and Turkey (3), with single studies from the United Arab Emirates and Iraq. Despite various surveillance periods, clinical definitions, and antibody cut-off values used across the studies, the reported seroprevalence of pertussis antibodies suggested that adolescents and adults are commonly exposed to pertussis in the community and that vaccine-acquired immunity from childhood wanes. Few countries in the Middle East include a diphtheria-tetanus-acellular pertussis (Tdap) booster for adolescents on the national schedule. Israel was the only country with epidemiological data in a population that received Tdap, and the study showed that after the introduction of the adolescent booster dose, there was decrease in pertussis among children aged 5-14 years. To conclude, results from the Middle East suggest that in common with other regions, pertussis is widely circulating and that it might be shifting towards older age groups.
尽管有现代白喉-破伤风-百日咳(DTP)疫苗且疫苗接种覆盖率很高,但全球范围内仍观察到百日咳有所复发。在北美和欧洲,儿童中的高疫苗接种覆盖率已导致特定年龄的感染高峰发病率从婴儿转向大龄儿童和青少年。然而,关于中东大龄儿童和成人中百日咳的流行情况,人们了解得要少得多。我们对MEDLINE、EMBASE和BIOSIS进行了系统检索,以找出1990年1月1日至2019年6月17日期间发表的、有关中东学龄儿童、青少年和成人百日咳流行病学、疾病负担及死亡率的研究。由于所使用的方法各不相同,无法进行统计比较,因此对纳入的研究进行了叙述性综述。结果显示,大多数中东国家的监测数据薄弱或缺失,在确定的24项流行病学研究中,大多数来自伊朗(14项)、以色列(4项)和土耳其(3项),阿拉伯联合酋长国和伊拉克各有1项研究。尽管各项研究的监测期、临床定义和抗体临界值各不相同,但报告的百日咳抗体血清阳性率表明,青少年和成人在社区中普遍接触百日咳,且儿童期获得的疫苗免疫力会逐渐减弱。中东很少有国家将白喉-破伤风-无细胞百日咳(Tdap)加强疫苗纳入青少年国家免疫规划。以色列是唯一一个有在接种Tdap人群中的流行病学数据的国家,该研究表明,引入青少年加强剂量后,5至14岁儿童中的百日咳有所减少。总之,中东地区的结果表明,与其他地区一样,百日咳广泛传播,且可能正转向年龄更大的人群。